Instalab

Ammonia Test Blood

Catch liver detoxification failure before it reaches your brain.

Should you take a Ammonia test?

This test is most useful if any of these apply to you.

Living With Liver Disease
See whether your liver's detoxification system is keeping up, even when you feel stable.
Experiencing Brain Fog or Confusion
This test can reveal whether rising ammonia is behind unexplained cognitive changes.
Taking Valproic Acid
This medication raises ammonia in up to 36% of users. Track whether it is affecting you.
Family History of Metabolic Disorders
Inherited urea cycle defects can cause dangerous ammonia spikes. Baseline testing gives you a reference point.

About Ammonia

Your liver quietly handles one of the most toxic waste products your body makes every day. Ammonia, a byproduct of protein breakdown and gut bacteria activity, must be converted to harmless urea and flushed out through your kidneys. When this system falters, ammonia rises in the blood and can cross into the brain, causing confusion, personality changes, and in severe cases, coma.

A blood ammonia test reveals whether your body's nitrogen disposal system is working. For anyone with liver disease, a family history of inherited metabolic conditions, or unexplained neurological symptoms, this number can be the difference between early intervention and a crisis.

What Ammonia Is and Where It Comes From

Ammonia is a small nitrogen-containing molecule (chemical formula NH3) that exists mostly as ammonium (NH4+) in blood. It is not a protein, enzyme, or hormone. It is a metabolic waste product, and your body generates it continuously from several sources.

The largest source is your gut. Bacteria in your colon break down dietary protein and urea, releasing ammonia directly into the blood flowing to your liver. Your muscles generate ammonia during intense exercise when they burn amino acids for fuel. Your kidneys also produce ammonia as part of their acid-balancing work.

Your liver is the central clearinghouse. Specialized liver cells run a process called the urea cycle, which converts ammonia into urea, a much less toxic molecule that leaves through your urine. A backup system exists in your muscles and brain cells, where an enzyme called glutamine synthetase combines ammonia with another molecule (glutamate) to form glutamine. When the liver fails or these backup systems are overwhelmed, ammonia accumulates in your blood.

Liver Disease and Hepatic Encephalopathy

The most studied role for blood ammonia is in liver disease. When cirrhosis (permanent scarring of the liver) disrupts the urea cycle, ammonia builds up and crosses into the brain, causing a condition called hepatic encephalopathy, or HE. This ranges from subtle difficulty concentrating and personality changes to full coma.

In a study of 754 clinically stable outpatients with cirrhosis, ammonia normalized to the lab's upper limit of normal (a ratio called AMM-ULN) independently predicted both hospitalizations for liver-related complications and death. People with AMM-ULN above 1.4 had roughly three and a half times the rate of complications compared to those below that threshold, and about double the mortality risk. Ammonia outperformed traditional severity scores like MELD and Child-Pugh for predicting who would end up hospitalized.

If you have cirrhosis, this means an ammonia level more than 40% above your lab's normal ceiling puts you in a meaningfully higher risk category, even if you feel well. This is exactly the kind of early warning that can guide treatment decisions before a crisis hits.

Acute Liver Failure and Acute Decompensation

In more acute settings, ammonia carries even more prognostic weight. Among 498 patients with acutely decompensated cirrhosis, an ammonia level at or above 79.5 µmol/L (about 135 µg/dL) at admission was associated with 28-day mortality of 61.5%, compared to 26.6% in those below that threshold. Ammonia remained an independent predictor of death after adjusting for organ failure severity.

In acute liver failure, data from 1,186 patients showed that each 1 µmol/L increase in admission ammonia raised the odds of 21-day death by about 0.5%. Levels above 100 µmol/L predicted severe brain swelling and high-grade encephalopathy. For these patients, treatments that actively clear ammonia from the blood, such as continuous kidney-replacement therapy, were associated with roughly 50% lower odds of death compared to intermittent dialysis.

Urea Cycle Disorders

Inherited defects in the urea cycle are rare but life-threatening. In more than 100 patients with urea cycle disorders, fasting ammonia correlated strongly with daily ammonia exposure. People whose fasting ammonia was at or above the upper limit of normal were about 4.5 times more likely to have a hyperammonemic crisis over 12 months than those with levels below half the upper limit. In patients 6 years and older, that relative risk jumped to 20-fold.

For families managing a known urea cycle disorder, regular fasting ammonia checks are one of the most direct tools for adjusting treatment intensity and catching worsening control before a crisis.

Emerging Links: Cognitive Decline and Sepsis

Early evidence connects ammonia to conditions beyond liver disease. A large study of over 1,000 Chinese adults across the Alzheimer's disease spectrum found elevated blood ammonia at each stage of cognitive decline, from subjective memory complaints through mild impairment to diagnosed Alzheimer's. This research is cross-sectional, meaning it shows an association, not proof of causation. But ammonia's known ability to disrupt brain cell function makes the connection biologically plausible.

In sepsis, admission ammonia in 316 emergency department patients was an independent predictor of 28-day mortality, with predictive accuracy comparable to the SOFA organ-failure score. Ammonia may flag a specific type of metabolic breakdown during severe infection that standard inflammatory markers miss.

Reference Ranges

Ammonia reference ranges vary significantly between labs due to differences in sample handling, assay methods, and local calibration. Most clinical labs report a normal range for venous ammonia somewhere in the range of 15 to 45 µmol/L (roughly 25 to 75 µg/dL), but you should always interpret your result against your own lab's stated upper limit of normal (ULN). The most clinically validated way to interpret your number is as a ratio of your result to that ULN.

TierAMM-ULN RatioWhat It Suggests
NormalBelow 1.0Liver detoxification is keeping up with ammonia production.
Mildly elevated1.0 to 1.4Ammonia is above normal. In cirrhosis, crisis risk begins to rise. Worth monitoring.
High riskAbove 1.4In cirrhosis, associated with roughly 3.5 times higher rate of liver-related hospitalizations and about double the mortality risk.

These tiers come from studies of patients with cirrhosis and may not apply identically to people without liver disease. Always compare your results within the same lab over time for the most meaningful trend.

When Results Can Be Misleading

Ammonia is one of the most analytically fragile blood tests. The number on your report can be distorted by factors that have nothing to do with your actual ammonia level. Understanding these is essential before acting on a result.

  • Sample handling: Ammonia rises rapidly in blood sitting at room temperature. Tubes must be placed on ice immediately and processed within 15 to 30 minutes. A delay of even 30 minutes at room temperature can produce a falsely elevated result.
  • Tourniquet and fist-clenching: Squeezing your fist during the blood draw causes local muscle cells to release ammonia. A prolonged tourniquet has a similar effect. Both can artificially raise the number.
  • Recent protein intake: A protein-rich meal increased ammonia by 12% to 18% within one to two hours in patients with cirrhosis. Fasting samples are more reliable.
  • Valproic acid (an antiseizure medication): This drug raises blood ammonia in roughly 17% to 36% of patients taking it, even without causing liver damage. If you take valproic acid, your elevated ammonia may reflect a drug side effect rather than liver dysfunction.

Up to 40% of hospitalized patients with confirmed hepatic encephalopathy have ammonia levels within the normal range. This means a single normal result does not rule out a problem, and a single elevated result does not confirm one. Context matters more than any individual number.

Tracking Your Trend

Because single ammonia measurements are so variable, serial tracking is far more valuable than any snapshot. A trend tells you whether your liver's detoxification capacity is holding steady, improving with treatment, or quietly declining.

If you have cirrhosis or a known metabolic condition, get a baseline ammonia (fasting, with proper sample handling) and retest every 3 to 6 months, or sooner if symptoms change. If you are making dietary or medication changes aimed at lowering ammonia, retest after 4 to 8 weeks to see whether the intervention is working. In acute settings, ammonia tends to fall over the first 24 to 36 hours of treatment and then stabilizes, so repeated checks beyond that window add limited value unless your clinical picture is changing.

Always use the same lab for serial comparisons. Switching labs introduces variation from different assays and handling protocols that can mimic a real change when none has occurred.

What to Do With an Abnormal Result

If your ammonia comes back elevated, the first step is confirming the result. Request a repeat draw with strict pre-analytical handling: fasting, no tourniquet or fist-clenching, sample on ice, processed within 15 minutes. A confirmed elevation above 1.4 times your lab's upper limit should prompt a workup.

Companion tests to order include a comprehensive metabolic panel (to check liver enzymes, albumin, and bilirubin), a complete blood count, and an INR (a measure of blood-clotting speed that reflects liver synthetic function). If liver disease is suspected, a hepatologist or gastroenterologist can assess for cirrhosis with imaging and elastography. If the elevation is unexplained and no liver disease is apparent, inherited metabolic conditions like urea cycle defects should be considered, especially in younger adults or those with a family history of unexplained encephalopathy.

If you are taking valproic acid or other antiseizure medications, discuss the finding with your prescribing physician. Drug-induced ammonia elevation is common with this class and may be manageable with dose adjustment or carnitine supplementation without discontinuing the medication.

What Moves This Biomarker

Evidence-backed interventions that affect your Ammonia level

Decrease
Take lactulose (a non-absorbable sugar that traps ammonia in the gut)
Lactulose is the first-line treatment for elevated ammonia in liver disease. It works by acidifying the colon, which converts ammonia into ammonium that cannot be reabsorbed, and by promoting bowel movements that physically remove ammonia-producing bacteria. In a randomized trial of 120 patients with overt hepatic encephalopathy, lactulose alone achieved complete reversal of encephalopathy in about 51% to 53% of patients. In a prevention trial of 140 cirrhosis patients who had recovered from an HE episode, lactulose reduced recurrence from 47% to 20% over 14 months. Arterial ammonia levels fell significantly in all lactulose-treated groups studied.
MedicationStrong Evidence
Decrease
Take rifaximin (a gut-targeted antibiotic) in addition to lactulose
Adding rifaximin to lactulose reduces ammonia-producing gut bacteria without being absorbed into the bloodstream. In a randomized trial of 120 patients with overt HE, the combination achieved complete reversal in 76% versus 51% with lactulose alone, and cut mortality from 49% to 24%. A Cochrane review of 41 trials involving 4,545 patients found that combining rifaximin with a non-absorbable disaccharide (like lactulose) likely reduces mortality by about 31% compared to lactulose alone. This combination is now the standard of care for preventing recurrent hepatic encephalopathy.
MedicationStrong Evidence
Increase
Take valproic acid (an antiseizure and mood-stabilizing medication)
Valproic acid raises blood ammonia in 17% to 36% of people taking it, even at therapeutic doses and with normal liver function. It does this by interfering with the urea cycle and depleting carnitine, a molecule your cells need to process certain fats and waste products. In a retrospective study of 347 psychiatric inpatients on valproic acid, 36% developed hyperammonemia, though more than half of those had no symptoms. When symptoms do occur, they range from nausea and fatigue to confusion and seizures. The ammonia elevation is dose-dependent, and adding other antiseizure medications (especially phenytoin or topiramate) significantly increases the risk.
MedicationStrong Evidence
Decrease
Receive intravenous L-ornithine L-aspartate (LOLA)
LOLA supplies the building blocks for ammonia detoxification through both the urea cycle and the glutamine pathway. In a randomized trial of 193 patients with cirrhosis and overt HE, intravenous LOLA (30 g/day for 5 days, added to standard lactulose) significantly reduced venous ammonia and shortened recovery time from an average of 2.5 days to 1.9 days compared to placebo. A network meta-analysis ranked LOLA as the most effective single agent for ammonia reduction, ahead of lactulose and probiotics.
MedicationModerate Evidence
Decrease
Take probiotics
Probiotics reduce ammonia by shifting gut bacteria away from ammonia-producing species. A meta-analysis of 9 randomized trials involving 776 patients with minimal hepatic encephalopathy found probiotics significantly reduced serum ammonia compared to placebo. In a network meta-analysis of 25 trials, probiotics ranked behind LOLA and lactulose for ammonia reduction but were effective for reversing minimal encephalopathy and had fewer side effects than most alternatives.
SupplementModerate Evidence

Frequently Asked Questions

References

20 studies
  1. T. Tranah, M. Ballester, J. Carbonell-asins, J. Ampuero, G. Alexandrino, a. Caracostea, Y. Sanchez-torrijos, K. Thomsen, a. Kerbert, M. Capilla-lozano, M. Romero-gomez, D. Escudero-garcía, C. Montoliu, R. Jalan, D. ShawcrossJournal of Hepatology2022
  2. Shalimar, M. Sheikh, R. Mookerjee, B. Agarwal, S. Acharya, R. JalanHepatology2019
  3. B. H. Lee, G. Diaz, W. Rhead, U. Lichter-konecki, a. Feigenbaum, S. Berry, C. L. Mons, J. Bartley, N. Longo, S. Nagamani, W. Berquist, R. Gallagher, D. Bartholomew, C. Harding, M. Korson, S. Mccandless, W. E. Smith, S. Cederbaum, D. Wong, J. Merritt, a. Schulze, J. Vockley, G. Vockley, D. Kronn, R. Zori, M. Summar, D. a. Milikien, M. Marino, D. Coakley, M. Mokhtarani, B. ScharschmidtGenetics in Medicine2014